Patient-derived xenograft (PDX) models have high consistency with their primary tumors in terms of genetics, pathology, and biological characteristics. Being perfect clinical response to the drug, this model shows a good prospect in tumor individualized treatment. It can be used to screen tumor target drug and guide clinical medication effectively. In this review, we focused on the evaluation strategy of PDX models based on chemotherapeutics screening, summarized the standards and quality control requirements of PDX model. We proposed four different ways to evaluate the traceability of models, including histomorphology detection, sequencing analysis, tumor specific markers determination and STR testing. Furthermore, chemotherapeutics effect can be evaluated by measure of drug toxicity, gauge tumor volume and establishment of TGD mathematical model. All of these methods applicated in the PDX models provide perfect strategy for guiding tumor individualized treatment.